Effect of uncleaved caspase 3 level on AML patient survival. The plots show Kaplan-Meier survival curves for AML patients with the lowest, middle, and highest thirds of normalized caspase 3 levels. Data shown are for all patients (lower two thirds, 123 patients; upper one third, 62 patients) (A), for patients with favorable and intermediate cytogenetic abnormalities (lower two thirds, 67 patients; upper one third, 36 patients) (B), and for patients with poor cytogenetic markers (lower two thirds, 56 patients; upper one third, 26 patients) (C).